Clinical Trials

Emtricitabine has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 for viral infectious diseases, including HIV-1, HIV-2, Hepatitis B, and SARS-CoV-2. Prominent sponsors such as the National Institute of Allergy and Infectious Diseases (NIAID), ANRS, and Boehringer Ingelheim have supported these studies to assess therapeutic efficacy, drug interactions, and regimen optimization. While many trials are completed, several Phase 2 and Phase 3 studies focused on combination antiretroviral therapies remain actively recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07708727 RECRUITING
HIV-1-infection
Gilead Sciences
 2026-07-29 PHASE2; PHASE3
NCT03304717 WITHDRAWN
Aicardi Goutières Syndrome
Children's Hospital of Philadelphia
 2025-12 PHASE1; PHASE2
NCT07792096 NOT_YET_RECRUITING
HIV Infection
University College, London
 2026-11 PHASE3
NCT07266831 RECRUITING
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC
 2025-12-18 PHASE2; PHASE3
NCT07497594 RECRUITING
Contact With or Exposure to Human Immunodeficiency Virus
Oswaldo Cruz Foundation
 2026-02-03
NCT07711223 RECRUITING
Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
 2025-11-07 PHASE1; PHASE2
NCT07616739 NOT_YET_RECRUITING
HIV-1-infection
Fundación Huésped
 2026-06-15 PHASE4
NCT07795307 NOT_YET_RECRUITING
Alzheimer's Disease
Brigham and Women's Hospital
 2026-12 PHASE1
NCT07288190 NOT_YET_RECRUITING
Pregnancy; HIV Infections
HIV Prevention Trials Network
 2026-05-15 PHASE2
NCT07055451 ACTIVE_NOT_RECRUITING
HIV-1-infection
Gilead Sciences
 2025-08-12 PHASE1
NCT06203132 RECRUITING
HIV-1-infection
ANRS, Emerging Infectious Diseases
 2025-01-27 PHASE3
NCT06544733 ACTIVE_NOT_RECRUITING
HIV-1-Infection
Gilead Sciences
 2024-08-20 PHASE2; PHASE3
NCT05813964 RECRUITING
HIV/AIDS
ANRS, Emerging Infectious Diseases
 2024-06-05 PHASE3
NCT07071623 RECRUITING
Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC
 2025-11-10 PHASE3
NCT06338826 NOT_YET_RECRUITING
HIV Infections; HBV Coinfection
ANRS, Emerging Infectious Diseases
 2025-02-01 PHASE2
NCT04520074 RECRUITING
Ovarian Cancer
Fudan University
 2021-10-08 PHASE3
NCT06891066 ACTIVE_NOT_RECRUITING
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC
 2025-04-14 PHASE2
NCT07645287 RECRUITING
HIV-1-infection
Gilead Sciences
 2026-06-15 PHASE2
NCT07044297 RECRUITING
Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC
 2025-07-31 PHASE3
NCT07476339 RECRUITING
HIV -1 Infection; HIV (Human Immunodeficiency Virus); HIV; HIV 1 Infection
CAN Community Health
 2026-06-17 PHASE4
NCT07202546 RECRUITING
HIV Infections
ViiV Healthcare
 2026-02-11 PHASE2
NCT05957913 ENROLLING_BY_INVITATION
Multiple Sclerosis
Massachusetts General Hospital
 2023-06-05 PHASE2
NCT02656511 ACTIVE_NOT_RECRUITING
HIV
University of California, San Francisco
 2015-12 PHASE4
NCT07349758 RECRUITING
Healthy Volunteer; HIV Prevention
Johns Hopkins University
 2026-01-06 PHASE1
NCT07788846 NOT_YET_RECRUITING
Hemostasis; Surgical Blood Loss; Amputation Stump; Hemorrhage
Adichunchanagiri Institute of Medical Sciences, B G Nagara
 2026-09
NCT06830668 NOT_YET_RECRUITING
HIV Infection; HIV
National Center for AIDS/STD Control and Prevention, China CDC
 2025-02-28 PHASE4
NCT07031063 RECRUITING
HIV Infection; Metabolic Syndrome; Antiretroviral Treatment
Instituto Mexicano del Seguro Social
 2025-04-01 PHASE4
NCT07584122 RECRUITING
HIV Infections
Oswaldo Cruz Foundation
 2025-09-01
NCT06511063 RECRUITING
Long Covid
Icahn School of Medicine at Mount Sinai
 2024-10-01 PHASE2
NCT07210528 ACTIVE_NOT_RECRUITING
Mild Cognitive Impairment (MCI); Alzheimer Dementia (AD)
National University Hospital, Singapore
 2025-06-30 PHASE1
NCT06374758 ACTIVE_NOT_RECRUITING
HIV Infections; ART; Noncompliance, Patient
University of Missouri-Columbia
 2024-04-29 PHASE4
NCT06101342 ACTIVE_NOT_RECRUITING
Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
 2023-12-13 PHASE2
NCT07532304 COMPLETED
Healthy
Merck Sharp & Dohme LLC
 2026-05-11 PHASE1
NCT06101329 ACTIVE_NOT_RECRUITING
Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
 2023-11-17 PHASE2
NCT07678268 RECRUITING
HIV Infection; Antiretroviral Therapy; Lentivirus Infections
Instituto Mexicano del Seguro Social
 2025-07-10 PHASE4
NCT05924438 ACTIVE_NOT_RECRUITING
HIV-1-infection
Professor Francois Venter
 2023-11-08 PHASE3
NCT07075146 RECRUITING
HIV - Human Immunodeficiency Virus; Obesity; Overweight and/or Obesity
José Antonio Mata Marín
 2025-05-05 PHASE3
NCT06513312 ACTIVE_NOT_RECRUITING
Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
 2024-10-07 PHASE2
NCT06250504 RECRUITING
HIV Infections
Africa Health Research Institute
 2024-02-27 PHASE3
NCT06630286 ACTIVE_NOT_RECRUITING
HIV-1-infection
Gilead Sciences
 2024-10-09 PHASE3
NCT05979311 ACTIVE_NOT_RECRUITING
HIV; HIV Infections
ViiV Healthcare
 2024-02-21 PHASE3
NCT06613685 TERMINATED
HIV-1-infection
Gilead Sciences
 2024-10-21 PHASE2; PHASE3
NCT06907056 RECRUITING
HIV Infection
José Antonio Mata Marín
 2023-11-09 PHASE4
NCT07138144 RECRUITING
HIV Infections
José Antonio Mata Marín
 2025-07-12 PHASE4
NCT06435026 COMPLETED
HIV; Prevention; Pregnancy
University of North Carolina, Chapel Hill
 2024-06-18 PHASE2
NCT05911360 COMPLETED
HIV; HIV Infections
ViiV Healthcare
 2023-07-07 PHASE3
NCT06133686 NOT_YET_RECRUITING
HIV
MRC/UVRI and LSHTM Uganda Research Unit
 2024-04-01 PHASE3
NCT07006246 ACTIVE_NOT_RECRUITING
HIV Infection
Professor Francois Venter
 2023-05-19 PHASE4
NCT06138600 UNKNOWN
HIV Infections
University of Witwatersrand, South Africa
 2023-11-01 PHASE3
NCT05222945 NOT_YET_RECRUITING
HIV-1-infection
ANRS, Emerging Infectious Diseases
 2025-04-01
NCT06273943 NOT_YET_RECRUITING
Prevention
ANRS, Emerging Infectious Diseases
 2024-04-01 PHASE3
NCT06333808 ACTIVE_NOT_RECRUITING
HIV-1-infection
Gilead Sciences
 2024-03-25 PHASE3
NCT05705349 ACTIVE_NOT_RECRUITING
HIV-1 Infection
Merck Sharp & Dohme LLC
 2023-03-08 PHASE3
NCT04820933 COMPLETED
HIV I Infection; Cardiovascular Risk Factor; Lipid Metabolism Disorders
University of Texas Southwestern Medical Center
 2024-03-01 EARLY_PHASE1
NCT05898841 COMPLETED
HIV Infections; Fatty Liver Disease
Fundacion SEIMC-GESIDA
 2023-05-26 PHASE4
NCT05993767 COMPLETED
HIV Infection
PENTA Foundation
 2024-12-11 PHASE2
NCT02016924 ACTIVE_NOT_RECRUITING
Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Gilead Sciences
 2014-01-16 PHASE2; PHASE3
NCT06816043 COMPLETED
Healthy
Merck Sharp & Dohme LLC
 2025-02-21 PHASE1
NCT06719310 COMPLETED
Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
 2024-08-28 PHASE1; PHASE2
NCT02881320 ACTIVE_NOT_RECRUITING
HIV-1 Infection
Gilead Sciences
 2016-09-21 PHASE2; PHASE3
NCT04760691 COMPLETED
HIV; Prophylaxis; Transgender
Johns Hopkins University
 2021-03-01 PHASE1
NCT05463783 UNKNOWN
HIV Infections; Obesity
East Carolina University
 2023-03-14 PHASE4
NCT04564547 COMPLETED
HIV-1 Infection
Merck Sharp & Dohme LLC
 2021-03-09 PHASE2
NCT04066881 COMPLETED
HIV Infections
MRC/UVRI and LSHTM Uganda Research Unit
 2020-12-15 PHASE2
NCT05289986 TERMINATED
Hiv
Chelsea and Westminster NHS Foundation Trust
 2023-11-21 PHASE4
NCT05663892 ACTIVE_NOT_RECRUITING
Hiv; Transgenderism
Maple Leaf Research
 2022-11-23 PHASE4
NCT05630755 ACTIVE_NOT_RECRUITING
HIV-1 Infection
Merck Sharp & Dohme LLC
 2023-02-17 PHASE3
NCT04636437 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2021-07-27 PHASE4
NCT05057858 COMPLETED
HIV Infections
University of Washington
 2022-04-25 PHASE2
NCT03058835 COMPLETED
PrEP Adherence Monitoring
Rutgers, The State University of New Jersey
 2016-09 PHASE4
NCT04530630 COMPLETED
HIV Infections; Renal Transplant Rejection
Weill Medical College of Cornell University
 2020-11-09 PHASE4
NCT06356194 COMPLETED
Healthy Volunteer Study
Atea Pharmaceuticals, Inc.
 2024-04-15 PHASE1
NCT04994509 ACTIVE_NOT_RECRUITING
Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
 2021-08-30 PHASE3
NCT06278389 COMPLETED
Healthy Adult Participants
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
 2024-01-24 PHASE1
NCT04880395 COMPLETED
HIV-1-infection
Fundación Huésped
 2021-05-17 PHASE4
NCT04388904 COMPLETED
HIV-1-infection
The Crofoot Research Center, Inc.
 2021-09-01 PHASE4
NCT05602506 COMPLETED
HIV Infections
Fundacion Clinic per a la Recerca Biomédica
 2022-11-15 PHASE4
NCT05122754 UNKNOWN
HIV-1-infection
Shanghai Public Health Clinical Center
 2021-12-08 PHASE4
NCT04884139 COMPLETED
HIV-1-infection
Fundacion SEIMC-GESIDA
 2021-07-14 PHASE4
NCT05549180 COMPLETED
HIV Infections
Fundacion SEIMC-GESIDA
 2022-10-06 PHASE4
NCT04616963 ACTIVE_NOT_RECRUITING
Hiv; Hormone Therapy
University of California, San Diego
 2019-10-24 PHASE4
NCT04734652 COMPLETED
HIV/AIDS; Tuberculosis, Pulmonary
Centre for the AIDS Programme of Research in South Africa
 2022-02-18 PHASE2
NCT03675815 COMPLETED
HIV Infections
Kirby Institute
 2019-12-05 PHASE4
NCT06005610 Recruiting
HIV I Infection
National Institute of Allergy and Infectious Diseases (NIAID)
 2024-01-04 Phase 2
NCT05405751 COMPLETED
HIV Infections
Fundacion SEIMC-GESIDA
 2022-07-04 PHASE4
NCT03464266 COMPLETED
Bone Demineralization; Hypoestrogenism; Subclinical Kidney Injury; Bone Microarchitecture
University of Washington
 2018-05-15 PHASE4
NCT05140954 COMPLETED
HIV Infections
University of Washington
 2023-04-10 PHASE2; PHASE3
NCT05458765 COMPLETED
Acceptability of Health Care; Adherence, Medication
Eastern Virginia Medical School
 2022-06-21 PHASE2
NCT03652623 COMPLETED
HIV/AIDS; Gender; Behavior and Behavior Mechanisms
Hektoen Institute for Medical Research
 2018-07-23 PHASE1; PHASE2
NCT05924438 Recruiting
HIV-1-infection
Professor Francois Venter|Africa Health Research Institute|Merck Sharp & Dohme LLC|University of Witwatersrand South Africa
 2023-11-08 Phase 3
NCT02562365 UNKNOWN
Ovarian Cancer
Xiaohua Wu MD
 2015-11 PHASE2
NCT06177574 COMPLETED
HIV Infections
Carmen Hidalgo Tenorio
 2020-10-27 PHASE4
NCT03386578 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2018-07-03 PHASE2
NCT04593680 ACTIVE_NOT_RECRUITING
Drug Interaction
Thai Red Cross AIDS Research Centre
 2022-01-24
NCT04549467 COMPLETED
Hiv; HIV-1-infection
Fundacion IDEAA
 2020-11-17 PHASE4
NCT06773754 ACTIVE_NOT_RECRUITING
Virally Suppressed People With HIV
National Taiwan University Hospital
 2022-06-14
NCT04442737 COMPLETED
HIV-1
Janssen Scientific Affairs, LLC
 2020-07-01 PHASE4
NCT04652700 TERMINATED
HIV Preexposure Prophylaxis
Merck Sharp & Dohme LLC
 2021-03-15 PHASE3
NCT04585737 COMPLETED
HIV I Infection
Charlotte-Paige Rolle, MD
 2020-10-05 PHASE4
NCT04644029 TERMINATED
HIV-I; Human Immunodeficiency Virus Type 1; Prophylaxis
Merck Sharp & Dohme LLC
 2021-02-24 PHASE3
NCT04890626 COMPLETED
SARS-CoV-2 Infection
Instituto de Investigación Hospital Universitario La Paz
 2020-04-04 PHASE3
NCT04692077 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2020-02-19 PHASE2
NCT04249037 TERMINATED
HIV/AIDS
University of Colorado, Denver
 2020-12-15 PHASE4
NCT04993872 UNKNOWN
HIV-infected Patient Kidney Transplant Recipient
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
 2022-09-29 PHASE4
NCT05159531 TERMINATED
HIV Infections
Unity Health Toronto
 2023-05-01 PHASE4
NCT03711253 UNKNOWN
Acute HIV Infection
University of Southern California
 2019-10-14 PHASE4
NCT05457530 WITHDRAWN
Body Weight Changes; Human Immunodeficiency Virus; ART; Obesity; Minority Health; BMD; Metabolic Syndrome; Fasting
Prism Health North Texas
 2022-08-01 PHASE3
NCT05243602 COMPLETED
HIV-1-infection
University of Nairobi
 2022-02-01 PHASE4
NCT03727152 COMPLETED
HIV
The HIV Netherlands Australia Thailand Research Collaboration
 2019-05-01 PHASE3
NCT05489406 COMPLETED
Hiv
Radboud University Medical Center
 2022-10-06 PHASE1
NCT04597424 COMPLETED
Unsafe Sex; Risk-Taking
ANRS, Emerging Infectious Diseases
 2021-01-19 PHASE3
NCT04870671 COMPLETED
HIV/AIDS; Adherence, Medication; Drug Use
Eastern Virginia Medical School
 2021-03-25 EARLY_PHASE1
NCT04824131 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2020-11-04 PHASE2
NCT04712058 UNKNOWN
HIV Infections
National Taiwan University Hospital
 2021-01-20
NCT04583267 UNKNOWN
HIV Infections
Yonsei University
 2018-08-28
NCT03797014 COMPLETED
HIV-1-infection; Hepatitis B
University of Maryland, Baltimore
 2019-04-30 PHASE4
NCT04233879 COMPLETED
HIV-1 Infection
Merck Sharp & Dohme LLC
 2020-02-28 PHASE3
NCT04483674 UNKNOWN
HIV Primary Infection
Anna Cruceta
 2020-12-04 PHASE2
NCT03954327 COMPLETED
Primary Biliary Cholangitis
University of Alberta
 2021-03-01 PHASE2
NCT04493216 TERMINATED
HIV Infections
ViiV Healthcare
 2020-11-18 PHASE2
NCT03734497 WITHDRAWN
Meniscus Disorder
Diskapi Teaching and Research Hospital
 2022-07
NCT04298697 COMPLETED
Human Immunodeficiency Virus
Emory University
 2020-02-28 PHASE4
NCT00799864 COMPLETED
HIV-1
Janssen Sciences Ireland UC
 2011-01 PHASE2
NCT04898699 COMPLETED
HIV
Columbia University
 2021-11-24 EARLY_PHASE1
NCT04542070 COMPLETED
HIV Infections
ViiV Healthcare
 2020-11-09 PHASE3
NCT04040075 TERMINATED
HIV-1-infection
Southampton Healthcare, Inc.
 2019-07-01 PHASE4
NCT04311957 UNKNOWN
HIV-1-infection; Antiretroviral Therapy
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
 2020-09-01 PHASE4
NCT03122262 COMPLETED
HIV-1 Infection
Professor Francois Venter
 2017-01-16 PHASE3
NCT03988387 COMPLETED
HIV
Columbia University
 2019-10-31
NCT03547908 COMPLETED
HIV-1/HBV Co-Infection
Gilead Sciences
 2018-05-30 PHASE3
NCT04712357 UNKNOWN
Covid19
Universidade Federal do Ceara
 2020-11-09
NCT04295460 UNKNOWN
HIV Infection
Hospitales Universitarios Virgen del Rocío
 2020-03-10 PHASE4
NCT04222283 UNKNOWN
HIV Infections
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
 2020-08-17 PHASE4
NCT04240509 UNKNOWN
HIV Infections; Sexually Transmitted Diseases
The Miriam Hospital
 2019-11-01 PHASE4
NCT04240210 TERMINATED
Human Immunodeficiency Virus
Midland Research Group, Inc.
 2019-09-17 PHASE4
NCT03826199 COMPLETED
Hiv
University of California, Los Angeles
 2019-08-23 PHASE4
NCT04538040 COMPLETED
HIV-1-infection
Quest Clinical Research
 2019-12-19 PHASE4
NCT03717129 COMPLETED
Healthy Volunteers
Johns Hopkins University
 2019-04-15 PHASE4
NCT03998176 COMPLETED
HIV-1-infection
University of Nebraska
 2019-10-09 PHASE4
NCT04302896 COMPLETED
Medication Adherence; HIV
Rhonda Brand
 2020-08-31 EARLY_PHASE1
NCT03656783 COMPLETED
HIV
Brigham and Women's Hospital
 2018-09-14 PHASE3
NCT03593655 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2019-01-14 PHASE2
NCT04223791 COMPLETED
HIV Infection
Merck Sharp & Dohme LLC
 2020-02-18 PHASE3
NCT04329442 WITHDRAWN
HIV/AIDS
University of Chicago
 2020-04-01
NCT04661397 COMPLETED
Healthy
Janssen Research & Development, LLC
 2021-01-05 PHASE1
NCT03251144 COMPLETED
HIV/AIDS; Antiviral Toxicity; Antiviral Drug Adverse Reaction; Mitochondrial Alteration
University of California, Los Angeles
 2019-04-01 PHASE1; PHASE2
NCT04853524 WITHDRAWN
Healthy
Janssen Research & Development, LLC
 2021-05-06 PHASE1
NCT04365660 TERMINATED
Osteosarcoma
Davidzon, Guido, M.D.
 2021-01-28 PHASE2
NCT04244448 COMPLETED
Healthy Volunteers
University Hospital, Caen
 2019-12-02 PHASE1
NCT04685512 COMPLETED
Covid19
University Hospital, Caen
 2020-11-18 PHASE2; PHASE3
NCT03858478 UNKNOWN
HIV Seropositivity
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
 2019-11-18 PHASE4
NCT03986697 WITHDRAWN
Coronary Artery Disease; Hiv
University of Liverpool
 2020-02-04 PHASE4
NCT04359095 COMPLETED
COVID-19
Universidad Nacional de Colombia
 2020-08-18 PHASE2; PHASE3
NCT03842488 UNKNOWN
HIV Infections
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
 2019-04 PHASE4
NCT02815566 COMPLETED
Osteoporosis; HIV; Menopause
University Health Network, Toronto
 2017-09-12 PHASE4
NCT04334928 COMPLETED
Coronavirus Infection
Plan Nacional sobre el Sida (PNS)
 2020-04-15 PHASE3
NCT05606055 COMPLETED
HIV-1-infection
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
 2020-12-01 PHASE4
NCT04519125 UNKNOWN
Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19
Hospital Universitario San Ignacio
 2020-08-30 PHASE2; PHASE3
NCT03348163 TERMINATED
HIV Infections
The University of Texas Health Science Center, Houston
 2018-06-06 PHASE4
NCT02859558 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2017-01-24 PHASE2
NCT04405271 TERMINATED
Healthcare Workers; COVID-19; SARS-CoV 2
Hospital Italiano de Buenos Aires
 2020-07-31 PHASE3
NCT03164564 ACTIVE_NOT_RECRUITING
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2017-11-07 PHASE3
NCT04424264 COMPLETED
HIV-1-infection; Tuberculosis
Professor Francois Venter
 2019-12-05 PHASE1
NCT03048422 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2018-01-19 PHASE3
NCT03255915 ACTIVE_NOT_RECRUITING
HIV Prevention
Oak Crest Institute of Science
 2018-09-20 EARLY_PHASE1
NCT04477096 COMPLETED
Healthy Subjects
Jiangsu Hansoh Pharmaceutical Co., Ltd.
 2020-08-03 PHASE1
NCT03512964 COMPLETED
Human Immunodeficiency Virus
Johns Hopkins University
 2016-11-29
NCT03120936 COMPLETED
Transgender Persons; Pre-Exposure Prophylaxis
Public Health Foundation Enterprises, Inc.
 2017-08-08 PHASE4
NCT03532425 TERMINATED
HIV-1-infection
University of Alberta
 2018-10-29 PHASE4
NCT04155554 UNKNOWN
HIV-1-infection
Azienda Ospedaliera Universitaria Senese
 2020-01-29 PHASE3
NCT03549312 UNKNOWN
HIV-1-infection; Hepatitis C, Chronic; Methadone Dependence; Opioid Dependence; Bone Diseases, Metabolic; HIV/AIDS; Co-infection; Buprenorphine Dependence; HCV Coinfection
Saskatchewan Health Authority - Regina Area
 2018-02-01 PHASE4
NCT03163277 TERMINATED
Hiv; Neurocognitive Dysfunction
Giovanni Di Perri
 2017-05-15 PHASE4
NCT04132674 UNKNOWN
Human Immunodeficiency Virus I Infection; Drug Use
Vancouver Infectious Diseases Centre
 2018-11-26 PHASE4
NCT03685500 COMPLETED
HIV Infections
Fundacion SEIMC-GESIDA
 2018-12-04 PHASE4
NCT03394196 TERMINATED
HIV-2 Infection
University of Washington
 2018-07-04
NCT02844634 COMPLETED
HIV; Syphilis
British Columbia Centre for Disease Control
 2018-05-15 PHASE4
NCT03693508 COMPLETED
HIV Infections; Severe Immunosuppression
Fundacion SEIMC-GESIDA
 2018-04-13 PHASE4
NCT03360682 COMPLETED
HIV-1-infection; Solid Organ Transplant
Fundacion Clinic per a la Recerca Biomédica
 2018-04-13 PHASE4
NCT02720094 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2016-12-19 PHASE2; PHASE3
NCT01854775 COMPLETED
Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Gilead Sciences
 2013-05-06 PHASE2; PHASE3
NCT03405194 WITHDRAWN
HIV/AIDS
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
 2018-05-01
NCT03771638 COMPLETED
Adherence, Medication; Risk Behavior; Pre-Exposure Prophylaxis; HIV Prevention
Public Health Foundation Enterprises, Inc.
 2019-02-01 PHASE4
NCT04236453 TERMINATED
Healthy
Janssen Pharmaceutica N.V., Belgium
 2020-01-23 PHASE1
NCT03499483 COMPLETED
HIV Prevention
Fenway Community Health
 2019-01-24 PHASE4
NCT04006704 COMPLETED
HIV-1
Janssen Pharmaceutica N.V., Belgium
 2019-10-10 PHASE1
NCT04054089 COMPLETED
HIV Infections
Cristina Mussini
 2020-01-23 PHASE4
NCT03502005 COMPLETED
Human Immunodeficiency Virus
Midland Research Group, Inc.
 2018-03-01 PHASE4
NCT02285114 COMPLETED
HIV-1
Gilead Sciences
 2015-01-20 PHASE2; PHASE3
NCT03275701 UNKNOWN
Infection, Human Immunodeficiency Virus
Mills Clinical Research
 2016-07
NCT03917420 COMPLETED
HIV/AIDS
University of North Carolina, Chapel Hill
 2019-03-26 PHASE1
NCT03631732 COMPLETED
HIV-1 Infection
Gilead Sciences
 2018-08-28 PHASE3
NCT02987530 COMPLETED
HIV-1 Infection
ANRS, Emerging Infectious Diseases
 2017-04-11 PHASE3
NCT03220152 UNKNOWN
HIV, Prevention
Oswaldo Cruz Foundation
 2017-07-10 PHASE4
NCT03033836 COMPLETED
HIV Infections
Fundación Huésped
 2015-12 PHASE4
NCT03120494 UNKNOWN
HIV/AIDS
Puerto Rico Community Network for Clinical Research on AIDS
 2016-11 PHASE4
NCT02962739 COMPLETED
Healthy Volunteers
University of Colorado, Denver
 2016-03 PHASE1
NCT02584140 COMPLETED
HIV Prevention
University of California, Los Angeles
 2016-05 PHASE4
NCT02150993 COMPLETED
HIV-2 Infection
ANRS, Emerging Infectious Diseases
 2016-01-26 PHASE2; PHASE3
NCT03327155 COMPLETED
HIV Prevention
Kirby Institute
 2017-11-16 PHASE3
NCT03067285 COMPLETED
HIV Infections
Fundacion SEIMC-GESIDA
 2017-09-08 PHASE4
NCT03836729 COMPLETED
HIV Infections
ViiV Healthcare
 2019-02-11 PHASE1
NCT03595709 COMPLETED
HIV Infections
Yu-Jay Corp.
 2018-12-06 PHASE3
NCT02870790 COMPLETED
HIV; STI
Kirby Institute
 2016-03 PHASE3
NCT02842086 ACTIVE_NOT_RECRUITING
Pre-Exposure Prophylaxis of HIV-1 Infection
Gilead Sciences
 2016-09-02 PHASE3
NCT03227861 COMPLETED
HIV-1
Janssen Scientific Affairs, LLC
 2017-07-31 PHASE3
NCT03110380 COMPLETED
HIV-1-infection
Gilead Sciences
 2017-06-12 PHASE3
NCT03074786 WITHDRAWN
HIV-1-infection
International Partnership for Microbicides, Inc.
 2017-11 PHASE2
NCT03405935 COMPLETED
HIV-1 Infection
Gilead Sciences
 2018-03-01 PHASE3
NCT02652793 COMPLETED
Human Immunodeficiency Virus
Judit Pich
 2015-11
NCT02616029 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-12-17 PHASE3
NCT03270969 COMPLETED
HIV Prevention
University of Nebraska
 2018-01-05 PHASE1
NCT03387462 COMPLETED
Adherence, Medication; Risk Behavior; Pre-Exposure Prophylaxis; HIV Prevention
Public Health Foundation Enterprises, Inc.
 2018-02-28 PHASE4
NCT02652260 COMPLETED
HIV-1; Central Nervous System
Merck Sharp & Dohme LLC
 2016-03-04 PHASE2
NCT02771054 COMPLETED
HIV
Göteborg University
 2016-05-02 PHASE4
NCT03202511 COMPLETED
Pre-Exposure Prophylaxis
Indiana University
 2017-06-23 EARLY_PHASE1
NCT02998320 COMPLETED
HIV Risk
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
 2017-03-10 PHASE3
NCT03060785 COMPLETED
HIV Prevention
Johns Hopkins University
 2016-03-08 PHASE1
NCT04050371 COMPLETED
HIV Prevention; Transgender Health
University of California, San Francisco
 2017-08-03 PHASE4
NCT03251690 COMPLETED
Anti-Retroviral Agents; Efavirenz; HIV-1-infection; Sustained Virologic Response; Dyslipidemias; Rilpivirine
Mahidol University
 2016-10-27
NCT03197961 COMPLETED
HIV/AIDS; Contraception
Sharon Achilles
 2017-11-17 EARLY_PHASE1
NCT03160105 COMPLETED
HIV-1-infection; Antiretroviral Therapy; Maintenance Therapy
Calmy Alexandra
 2017-05-19 PHASE4
NCT02831764 COMPLETED
Infection, Human Immunodeficiency Virus; HIV Infections
ViiV Healthcare
 2016-07-18 PHASE3
NCT02593409 UNKNOWN
HIV-1 Infections
MRC/UVRI and LSHTM Uganda Research Unit
 2017-05-25 PHASE4
NCT02831673 COMPLETED
Infection, Human Immunodeficiency Virus; HIV Infections
ViiV Healthcare
 2016-07-21 PHASE3
NCT03350672 COMPLETED
Hiv
Philadelphia Fight
 2017-11-16 PHASE4
NCT03493568 TERMINATED
HIV-1-infection
IRCCS San Raffaele
 2017-02-06 PHASE3
NCT01435018 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2013-10-01 PHASE3
NCT02616783 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-12-22 PHASE3
NCT03186482 COMPLETED
HIV
St. Stephens Clinical Research
 2017-06-01 PHASE1
NCT02660905 COMPLETED
Human Immunodeficiency Virus; Hepatitis C, Chronic
Ottawa Hospital Research Institute
 2016-04 PHASE3
NCT02832778 UNKNOWN
HIV
St Stephens Aids Trust
 2016-11-21 PHASE1
NCT02595021 UNKNOWN
Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Secondary Malignant Neoplasm of Large Intestine
Shanghai Gynecologic Oncology Group
 2015-07 PHASE2
NCT02904369 COMPLETED
HIV
CONRAD
 2016-10-06 PHASE1
NCT02495779 COMPLETED
Human Immunodeficiency Virus
James Egan
 2015-07
NCT02652624 COMPLETED
HIV-1 Infection
Gilead Sciences
 2016-02-19 PHASE3
NCT02499874 COMPLETED
HIV
St Stephens Aids Trust
 2015-08 PHASE1
NCT01829802 UNKNOWN
Chronic Infection With HIV
Pedro Cahn
 2014-05 PHASE4
NCT02707601 COMPLETED
HIV-1 Infection; HCV Infection
Gilead Sciences
 2016-04-01 PHASE3
NCT02826889 COMPLETED
Elective Posterior Lumbar Spinal Fusion for Spinal Stenosis; Spondylolisthesis; Spinal Fractures; Scoliosis or Tumors
Yonsei University
 2016-05-24
NCT02116660 TERMINATED
HIV Infections
Merck Sharp & Dohme LLC
 2014-09-03 PHASE2
NCT02042001 COMPLETED
Impaired Cognition; Depression/Anxiety; Poor Quality Sleep; Quality of Life; HIV-1 Infection
Azienda Ospedaliera San Gerardo di Monza
 2015-07-01 PHASE4
NCT02470650 WITHDRAWN
Patient Compliance; Antiretroviral Therapy Intolerance
Juan A. Arnaiz
 2015-06 PHASE4
NCT02770508 COMPLETED
HIV-1 Infection
Fundación Huésped
 2015-11 PHASE4
NCT02605954 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-11-18 PHASE3
NCT02327663 UNKNOWN
Hepatitis B, Chronic
Asian-Pacific Alliance of Liver Disease, Beijing
 2014-12 PHASE4
NCT02603107 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-11-20 PHASE3
NCT02607956 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-11-11 PHASE3
NCT02607930 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-11-13 PHASE3
NCT02529059 COMPLETED
HIV
St Stephens Aids Trust
 2015-11 PHASE4
NCT02968576 COMPLETED
Healthy Volunteers; Pharmacokinetics
University of Colorado, Denver
 2016-12
NCT02431247 COMPLETED
Immunodeficiency Virus Type 1, Human
Janssen Sciences Ireland UC
 2015-07-06 PHASE3
NCT02827643 UNKNOWN
Bone Density
Mahidol University
 2016-06
NCT03309566 COMPLETED
Healthy
Laboratorio Elea Phoenix S.A.
 2016-09-04 PHASE4
NCT02284035 COMPLETED
AIDS
Juan A. Arnaiz
 2015-09-27 PHASE3
NCT00524173 TERMINATED
Hepatitis B
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 2007-08-29 PHASE2
NCT02199613 COMPLETED
HIV Infection
University of British Columbia
 2014-10 PHASE4
NCT00743340 COMPLETED
HIV-1 Infection
Gilead Sciences
 2005-11-22 PHASE2
NCT02984852 COMPLETED
Healthy
Janssen Scientific Affairs, LLC
 2016-12 PHASE1
NCT02269917 COMPLETED
Human Immunodeficiency Virus Type 1
Janssen R&D Ireland
 2015-03 PHASE3
NCT02180438 COMPLETED
HIV-2 Infection
University of Washington
 2014-09 PHASE4
NCT02447016 TERMINATED
HIV
Sheba Medical Center
 2015-05 PHASE4
NCT01902186 TERMINATED
HIV Infection; Osteopenia
Giovanni Di Perri
 2014-09 PHASE4
NCT01869634 COMPLETED
Human Immunodeficiency Virus Infection
University of California, Davis
 2013-06 PHASE4
NCT02474303 COMPLETED
HIV/AIDS
Réseau Africain de Recherche sur le SIDA
 2015-07
NCT02431273 COMPLETED
Human Immunodeficiency Virus (HIV) Prophylaxis
Auritec Pharmaceuticals
 2015-06 EARLY_PHASE1
NCT02206555 COMPLETED
HIV
Kirby Institute
 2014-11-14 PHASE4
NCT01641367 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2013-02-22 PHASE4
NCT02449733 COMPLETED
HIV
Emory University
 2015-05
NCT02043015 COMPLETED
HIV
Emory University
 2015-02
NCT01061151 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2011-03-01 PHASE3
NCT02556333 TERMINATED
HIV
National Institute of Allergy and Infectious Diseases (NIAID)
 2015-09-16 PHASE2
NCT02198443 COMPLETED
HIV
Fundacion Clinic per a la Recerca Biomédica
 2015-06-06 PHASE4
NCT02345226 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-01-26 PHASE3
NCT02345252 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-01-26 PHASE3
NCT01632891 COMPLETED
HIV-1 Infection; Pf Subclinical Parasitemia
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2014-01-10 PHASE1; PHASE2
NCT02149888 COMPLETED
HIV; Human Immunodeficiency Virus
Unity Health Toronto
 2014-10 PHASE4
NCT02775929 COMPLETED
HIV Infection
University of Washington
 2012-11 PHASE4
NCT01509508 COMPLETED
HIV Infection
ANRS, Emerging Infectious Diseases
 2012-03
NCT02415595 TERMINATED
Infection, Human Immunodeficiency Virus
ViiV Healthcare
 2015-05-12 PHASE2
NCT02104700 COMPLETED
HIV
Philip Grant
 2014-04 PHASE2; PHASE3
NCT01781806 COMPLETED
HIV Prevention
University of California, Los Angeles
 2013-05 PHASE4
NCT02159599 COMPLETED
HIV Infection
Fundacion SEIMC-GESIDA
 2014-07 PHASE4
NCT02351908 COMPLETED
HIV
St Stephens Aids Trust
 2015-03 PHASE4
NCT01694420 COMPLETED
HIV
Duke University
 2012-09 PHASE3
NCT01352117 COMPLETED
HIV-1 Infection; Kaposi's Sarcoma
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2011-11-18 PHASE3
NCT01989611 UNKNOWN
HIV
Oswaldo Cruz Foundation
 2014-06
NCT01777997 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2013-04-25 PHASE4
NCT01003990 COMPLETED
HIV
Bristol-Myers Squibb
 2002-10 PHASE3
NCT02578550 COMPLETED
Healthy
Janssen Sciences Ireland UC
 2015-11 PHASE1
NCT02246998 COMPLETED
HIV-1 Infection
Gilead Sciences
 2014-12-15 PHASE4
NCT01605890 COMPLETED
HIV-2 Infection
ANRS, Emerging Infectious Diseases
 2012-07 PHASE2
NCT01291459 UNKNOWN
HIV
Association Pour la Recherche en Infectiologie
 2011-09 PHASE2
NCT02397694 COMPLETED
HIV-1 Infection
Gilead Sciences
 2015-03-23 PHASE2
NCT02211690 COMPLETED
Human Immunodeficiency Virus
Andrew Carr
 2014-08 PHASE4
NCT00936715 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2009-08 PHASE2
NCT01772823 COMPLETED
HIV Infection
University of North Carolina, Chapel Hill
 2012-11 PHASE2
NCT01769456 COMPLETED
HIV Infection
University of North Carolina, Chapel Hill
 2013-03 PHASE2
NCT01505114 COMPLETED
HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
 2012-06 PHASE2
NCT02475915 COMPLETED
Acute HIV Infection
SEARCH Research Foundation
 2015-01 PHASE1; PHASE2
NCT01721109 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2012-12-06 PHASE2; PHASE3
NCT01709084 COMPLETED
Human Immunodeficiency Virus-type 1 Infection
Janssen-Cilag International NV
 2013-10-02 PHASE3
NCT01929759 COMPLETED
HIV Disease
Massachusetts General Hospital
 2014-01
NCT01910402 COMPLETED
Infection, Human Immunodeficiency Virus; HIV Infections
ViiV Healthcare
 2013-08-22 PHASE3
NCT02530060 COMPLETED
Healthy
Janssen Pharmaceutical K.K.
 2015-08 PHASE4
NCT01669226 COMPLETED
Bulky Stage IIIC and IV Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
 2009-04 PHASE2
NCT02475135 COMPLETED
Healthy
Janssen Sciences Ireland UC
 2015-06-01 PHASE1
NCT02121795 COMPLETED
HIV-1 Infection
Gilead Sciences
 2014-05-06 PHASE3
NCT02220868 COMPLETED
Hepatitis C Infection; HIV Infection
Saint Michael's Medical Center
 2014-07 PHASE4
NCT01968551 COMPLETED
HIV-1; HIV Infections; Acquired Immunodeficiency Syndrome
Gilead Sciences
 2013-09-03 PHASE3
NCT02327702 UNKNOWN
Hepatitis B, Chronic; Pregnancy
Asian-Pacific Alliance of Liver Disease, Beijing
 2015-01 PHASE4
NCT02327676 UNKNOWN
Hepatitis B, Chronic
Asian-Pacific Alliance of Liver Disease, Beijing
 2015-01 PHASE4
NCT02327715 UNKNOWN
Hepatitis B, Chronic; Pregnancy
Asian-Pacific Alliance of Liver Disease, Beijing
 2015-01 PHASE4
NCT01614405 TERMINATED
Primary Biliary Cirrhosis
University of Alberta
 2012-06
NCT02327689 UNKNOWN
Hepatitis B, Chronic; Fibrosis
Asian-Pacific Alliance of Liver Disease, Beijing
 2015-01 PHASE4
NCT01687218 COMPLETED
HIV
CONRAD
 2013-09-25 PHASE2
NCT01967940 COMPLETED
HIV; HIV Infections; Acquired Immunodeficiency Syndrome
Gilead Sciences
 2013-10-25 PHASE3
NCT00074581 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2005-02 PHASE3
NCT02776748 COMPLETED
HIV Pre-exposure Prophylaxis During Breastfeeding
University of Washington
 2015-01 PHASE2; PHASE3
NCT01285050 COMPLETED
HIV Infection; Hepatitis C
Johns Hopkins University
 2011-01 PHASE4
NCT01815736 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2013-03-27 PHASE3
NCT02285374 UNKNOWN
HIV
St Stephens Aids Trust
 2014-11 PHASE4
NCT01705574 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2012-10-24 PHASE3
NCT01632995 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2012-10
NCT02071082 COMPLETED
HIV; HBV
Gilead Sciences
 2014-02-25 PHASE3
NCT01327651 COMPLETED
HIV Infections
HIV Prevention Trials Network
 2011-08 PHASE2
NCT01803074 COMPLETED
Infection, Human Immunodeficiency Virus; HIV Infections
ViiV Healthcare
 2013-04-04 PHASE2
NCT01778413 COMPLETED
HIV
Anna Cruceta
 2013-06-03 PHASE4
NCT02065986 COMPLETED
HIV
MRC [ycm]
 2012-10 PHASE4
NCT01352715 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2012-03-13 PHASE3
NCT02203461 COMPLETED
Insulin Resistance
Technical University of Munich
 2014-07 PHASE1
NCT02583464 COMPLETED
Acquired Immunodeficiency Syndrome
Laboratorio Elea Phoenix S.A.
 2014-09 PHASE1
NCT01797445 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2013-03-12 PHASE3
NCT01154673 COMPLETED
Acute HIV Infection
University of Toronto
 2011-11 PHASE2; PHASE3
NCT01780506 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2012-12-26 PHASE3
NCT01818596 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2013-03-27 PHASE3
NCT04318210 COMPLETED
HIV Infections
Centers for Disease Control and Prevention
 2012-10
NCT01515813 WITHDRAWN
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2011-11 PHASE2
NCT01715636 COMPLETED
HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men
Andrew Carr
 2012-12 PHASE4
NCT01576731 COMPLETED
HIV Infection
Hospital Clinic of Barcelona
 2012-07 PHASE4
NCT01450189 COMPLETED
HIV
University of North Carolina, Chapel Hill
 2011-10
NCT01258439 COMPLETED
HIV; Cardiovascular Disease
St Vincent's Hospital, Sydney
 2010-11 PHASE4
NCT01400412 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2012-01-17 PHASE2
NCT01533272 COMPLETED
HIV Infection
Hospital Clinic of Barcelona
 2012-02 PHASE4
NCT01471821 COMPLETED
HIV Infection
Juan A. Arnaiz
 2011-10 PHASE4
NCT01040091 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2009-12 PHASE1
NCT01855867 COMPLETED
Human Immunodeficiency Virus
Kenneth H. Mayer, MD
 2013-05 PHASE4
NCT02097381 UNKNOWN
HIV Infection
University of Roma La Sapienza
 2010-04
NCT01690403 COMPLETED
Tuberculosis
Sanofi
 2012-12 PHASE1
NCT00458393 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2007-06 PHASE3
NCT01458977 COMPLETED
HIV; Dyslipidemia
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
 2012-01 PHASE4
NCT01694407 COMPLETED
HIV
CONRAD
 2013-02 PHASE1
NCT00525733 COMPLETED
HIV Infections
Rockefeller University
 2007-10
NCT01495702 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2011-12 PHASE3
NCT01701882 COMPLETED
HIV
St Stephens Aids Trust
 2012-09 PHASE3
NCT00924898 COMPLETED
Acute HIV Infection; HIV Infections
University of North Carolina, Chapel Hill
 2005-01 PHASE4
NCT01475838 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2011-11 PHASE3
NCT01641809 COMPLETED
Infection, Human Immunodeficiency Virus; HIV Infections
ViiV Healthcare
 2012-08-06 PHASE2
NCT01066962 COMPLETED
HIV Infections
ANRS, Emerging Infectious Diseases
 2010-08 PHASE3
NCT00557245 COMPLETED
HIV-1 Infections; HIV Infections
University of Washington
 2008-05 PHASE3
NCT00928187 COMPLETED
HIV; HIV Infections
ANRS, Emerging Infectious Diseases
 2009-11 PHASE3
NCT01332227 COMPLETED
HIV, Combination Therapy
Bristol-Myers Squibb
 2011-10 PHASE4
NCT01345630 TERMINATED
HIV-1
ViiV Healthcare
 2011-09 PHASE3
NCT01565889 COMPLETED
Hepatitis C; HIV
Gilead Sciences
 2012-03 PHASE1; PHASE2
NCT01330199 COMPLETED
Healthy Adult Females
University of North Carolina, Chapel Hill
 2012-02 PHASE1
NCT01033760 COMPLETED
HIV-1 Infections
ANRS, Emerging Infectious Diseases
 2010-04 PHASE3
NCT01796431 COMPLETED
HIV
St Stephens Aids Trust
 2013-03 PHASE1
NCT00759070 UNKNOWN
HIV Infections
Juan A. Arnaiz
 2008-09 PHASE4
NCT00811954 COMPLETED
HIV Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2009-05 PHASE3
NCT00984152 WITHDRAWN
HIV-1 Infections
Rush University Medical Center
 2011-06 PHASE3
NCT00491556 COMPLETED
HIV Infections
University of North Carolina, Chapel Hill
 2007-10
NCT01234116 COMPLETED
Human Immunodeficiency Virus
Henry Ford Health System
 2011-02 PHASE4
NCT01274780 COMPLETED
HIV-1
Juan A. Arnaiz
 2011-05 PHASE4
NCT01338025 TERMINATED
HIV Disease
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
 2011-03 PHASE4
NCT01583439 TERMINATED
HIV Infections
Harvard School of Public Health (HSPH)
 2012-09
NCT01403051 COMPLETED
HIV-1 Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2011-09 PHASE2
NCT01620944 TERMINATED
HIV
Bristol-Myers Squibb
 2012-07-31 PHASE3
NCT01565850 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2012-04 PHASE2
NCT00936195 WITHDRAWN
HIV Infection; Pregnancy; Breastfeeding; HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2010-01 PHASE3
NCT01335620 COMPLETED
HIV
Imperial College London
 2011-04 PHASE4
NCT01338883 COMPLETED
HIV-1 Infection
Tobira Therapeutics, Inc.
 2011-06 PHASE2
NCT00532168 COMPLETED
HIV Infections
Juan A. Arnaiz
 2007-09 PHASE4
NCT01533259 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2012-01 PHASE3
NCT01025427 COMPLETED
HIV; HIV Infections
University of California, San Francisco
 2009-12 PHASE4
NCT01562886 COMPLETED
HIV
Imperial College London
 2012-03 PHASE1
NCT01497899 COMPLETED
Acquired Immunodeficiency Syndrome; HIV Infections
Gilead Sciences
 2011-12-28 PHASE2
NCT01270802 COMPLETED
HIV
Indiana University
 2011-04 PHASE4
NCT00677300 COMPLETED
HIV Infections
Dallas VA Medical Center
 2009-01 PHASE4
NCT01309243 COMPLETED
HIV-1 Infection
Gilead Sciences
 2011-02 PHASE3
NCT00608569 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2009-03
NCT01225705 WITHDRAWN
HIV; Hepatitis C
University Hospital, Bonn
 2010-10 PHASE4
NCT00734344 COMPLETED
Acute HIV Infection
University of Alabama at Birmingham
 2008-09
NCT00705679 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2009-08 PHASE2
NCT02273310 COMPLETED
Sickle Cell Disease
University of Pennsylvania
 2009-07
NCT01102972 COMPLETED
Infection, Human Immunodeficiency Virus
ViiV Healthcare
 2010-04 PHASE4
NCT01602822 TERMINATED
HIV
Kenneth H. Mayer, MD
 2012-02 PHASE4
NCT00545558 COMPLETED
Hepatitis C; HIV Infections
University of Cincinnati
 2006-04 PHASE1
NCT01529749 COMPLETED
HIV-1 Infection
Felipe Garcia
 2012-02 PHASE4
NCT01227824 COMPLETED
Infection, Human Immunodeficiency Virus I
ViiV Healthcare
 2010-10-19 PHASE3
NCT00931801 COMPLETED
HIV
Community Research Initiative of New England
 2009-12 PHASE4
NCT00544128 COMPLETED
HIV Infections
International Medical Center of Japan
 2007-10 PHASE4
NCT00444379 COMPLETED
Kaposi's Sarcoma; HIV Infections
University of California, San Francisco
 2007-04 PHASE4
NCT01294761 COMPLETED
HIV Infections
National Center for Global Health and Medicine, Japan
 2011-02
NCT00507507 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2007-09 PHASE2
NCT00654147 COMPLETED
HIV Infections
Margaret A. Fischl, M.D.
 2008-04 PHASE2
NCT01252940 COMPLETED
HIV-1 Infection
Gilead Sciences
 2010-11 PHASE3
NCT00364793 COMPLETED
HIV Infections
Bristol-Myers Squibb
 2007-02 PHASE1; PHASE2
NCT01108510 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2010-04 PHASE3
NCT00737568 COMPLETED
Hepatitis B
Gilead Sciences
 2008-09 PHASE3
NCT00808002 COMPLETED
HIV Infections
Germans Trias i Pujol Hospital
 2009-02 PHASE3
NCT00824421 COMPLETED
HIV-1
Pfizer
 2009-02 PHASE2
NCT01276600 COMPLETED
HIV
HIV Prevention Trials Network
 2011-01 PHASE1
NCT01772940 COMPLETED
HIV-1 Infection
Centre Hospitalier Universitaire Saint Pierre
 2008-12 PHASE4
NCT01033942 COMPLETED
HIV
University of North Carolina, Chapel Hill
 2009-08 PHASE2
NCT01106586 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2010-04 PHASE3
NCT01095796 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2010-03 PHASE3
NCT01231555 TERMINATED
Infection, Human Immunodeficiency Virus
ViiV Healthcare
 2010-11-18 PHASE2
NCT01286740 COMPLETED
HIV-1 Infection
Gilead Sciences
 2011-01 PHASE2
NCT00573001 COMPLETED
HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2008-07 PHASE3
NCT00752856 COMPLETED
HIV Infections
University of California, San Diego
 2008-08-26 PHASE2
NCT00507689 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2007-09 PHASE2
NCT00391638 COMPLETED
Hepatitis B; HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2007-01 PHASE2; PHASE3
NCT00298363 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2006-04 PHASE2
NCT01928407 COMPLETED
HIV-1 Infection; Immunosuppression-related Infectious Disease
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
 2011-02-23 PHASE4
NCT00724711 COMPLETED
HIV Infection
Gilead Sciences
 2008-07 PHASE4
NCT00448669 COMPLETED
HIV Infections
Centers for Disease Control and Prevention
 2007-03 PHASE2; PHASE3
NCT00641641 COMPLETED
HIV Infection
Kirby Institute
 2008-03
NCT00335322 COMPLETED
Human Immunodeficiency Virus (HIV)
Kirby Institute
 2007-02 PHASE4
NCT00389207 COMPLETED
HIV Infections
Boehringer Ingelheim
 2006-10 PHASE3
NCT00943540 COMPLETED
HIV Infection; HIV Infections
Radboud University Medical Center
 2009-07 PHASE2
NCT00669487 COMPLETED
HIV Infections
SEARCH Research Foundation
 2008-04 PHASE3
NCT00869960 COMPLETED
Healthy
University of Alabama at Birmingham
 2009-03 PHASE4
NCT00615745 COMPLETED
HIV Infections
Gilead Sciences
 2008-04 PHASE4
NCT00958100 COMPLETED
HIV/AIDS; Antiretroviral Therapy; HIV Infections
Catholic University of the Sacred Heart
 2009-08 PHASE2
NCT00627055 COMPLETED
HIV Infections
The HIV Netherlands Australia Thailand Research Collaboration
 2008-05 PHASE4
NCT01108926 COMPLETED
HIV Infection; HIV Infections
St Stephens Aids Trust
 2010-06 PHASE1
NCT00357552 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2008-01
NCT00346567 COMPLETED
HIV Infections
Rigshospitalet, Denmark
 2006-06
NCT00931346 COMPLETED
HIV Infection
International AIDS Vaccine Initiative
 2009-10 PHASE1; PHASE2
NCT00089505 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2006-11 PHASE3
NCT00827112 COMPLETED
Human Immunodeficiency Virus-1
ViiV Healthcare
 2009-03 PHASE2
NCT00442962 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2007-05 PHASE4
NCT00949234 COMPLETED
HIV Prevention; HIV Infections
University of California, Los Angeles
 2010-03 PHASE2
NCT00971230 COMPLETED
HIV Infections
International AIDS Vaccine Initiative
 2009-10 PHASE1; PHASE2
NCT00551018 COMPLETED
HIV Infections
Merck Sharp & Dohme LLC
 2007-12 PHASE2
NCT00084136 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2005-05 PHASE4
NCT00099632 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2006-03 PHASE2
NCT00552240 COMPLETED
HIV Infections
Boehringer Ingelheim
 2007-09 PHASE4
NCT00242216 COMPLETED
HIV Infections
The University of Texas Health Science Center, Houston
 2004-05 PHASE4
NCT00076791 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2004-03 PHASE1
NCT00863668 WITHDRAWN
HIV Infection; HIV Infections
University of Minnesota
 2009-03
NCT00951015 COMPLETED
Infection, Human Immunodeficiency Virus
ViiV Healthcare
 2009-07-30 PHASE2
NCT00862823 COMPLETED
Healthy
University of Alabama at Birmingham
 2009-02 PHASE4
NCT00414518 COMPLETED
HIV Infections
University of Colorado, Denver
 2007-01
NCT00540449 COMPLETED
HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1
Tibotec Pharmaceuticals, Ireland
 2008-05 PHASE3
NCT00662545 COMPLETED
HIV Infections; Hepatitis B
University of California, San Francisco
 2008-04 PHASE4
NCT00768989 TERMINATED
HIV
Bristol-Myers Squibb
 2008-11 PHASE2
NCT00414635 COMPLETED
HIV Infections
Community Research Initiative of New England
 2006-08 PHASE4
NCT00549198 COMPLETED
Infection, Human Immunodeficiency Virus I; HIV Infection
GlaxoSmithKline
 2007-06 PHASE4
NCT00474435 UNKNOWN
Tuberculosis; HIV Infections
African Poverty Related Infection Oriented Research Initiative
 2008-11 PHASE2
NCT00302822 COMPLETED
HIV Infections; AIDS
French National Agency for Research on AIDS and Viral Hepatitis
 2006-04 PHASE3
NCT00892437 COMPLETED
HIV-1 Infection
Gilead Sciences
 2009-05 PHASE2
NCT00869557 COMPLETED
HIV; HIV Infections
Gilead Sciences
 2009-04 PHASE2
NCT00115609 COMPLETED
HIV Infections; Tuberculosis
French National Agency for Research on AIDS and Viral Hepatitis
 2006-01 PHASE3
NCT00118898 COMPLETED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2005-09 PHASE3
NCT00711009 COMPLETED
Human Immunodeficiency Virus Infection
Abbott
 2008-07 PHASE3
NCT00772902 COMPLETED
HIV-1
Gilead Sciences
 2008-10 PHASE4
NCT00885664 COMPLETED
HIV Infections
University of Cincinnati
 2005-10 PHASE4
NCT00757783 COMPLETED
HIV
Tibotec, Inc
 2008-10 PHASE4
NCT00039741 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2002-08 PHASE2; PHASE3
NCT00334256 COMPLETED
HIV Infection; Pregnancy
French National Agency for Research on AIDS and Viral Hepatitis
 2006-10 PHASE2
NCT00090779 TERMINATED
HIV Infections
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
 2005-01 PHASE2
NCT00660972 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2008-05 PHASE1
NCT00016718 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2001-08 PHASE1; PHASE2
NCT00476463 COMPLETED
Hepatitis B Virus; HIV Infections
The HIV Netherlands Australia Thailand Research Collaboration
 2005-04 PHASE2
NCT00380159 COMPLETED
Human Immunodeficiency Virus (HIV)-1 Infection
Alexion Pharmaceuticals, Inc.
 2006-09 PHASE2
NCT00528060 COMPLETED
HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2008-01 PHASE2
NCT00454337 COMPLETED
HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2007-05 PHASE3
NCT00192634 COMPLETED
HIV Infections
Kirby Institute
 2005-12 PHASE4
NCT00344461 COMPLETED
HIV
University of Maryland, Baltimore
 2004-03 PHASE4
NCT00362687 COMPLETED
HIV Infections
Gilead Sciences
 2006-11 PHASE4
NCT00534352 COMPLETED
HIV-1 Infection
Tibotec, Inc
 2008-01 PHASE2
NCT00244712 COMPLETED
HIV Infection
GlaxoSmithKline
 2005-07 PHASE4
NCT00307489 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2006-03 PHASE2
NCT00051831 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2003-10
NCT00120367 COMPLETED
Leukoencephalopathy, Progressive Multifocal; HIV Infections
French National Agency for Research on AIDS and Viral Hepatitis
 2005-04 PHASE2
NCT00365612 COMPLETED
HIV Infections
Gilead Sciences
 2006-07 PHASE4
NCT00105079 COMPLETED
HIV Infections
Hoffmann-La Roche
 2005-04 PHASE3
NCT00323492 COMPLETED
HIV Infections
Gilead Sciences
 2005-09 PHASE4
NCT00272779 COMPLETED
HIV Infections
Bristol-Myers Squibb
 2005-11 PHASE3
NCT00323544 COMPLETED
HIV Infections
Gilead Sciences
 2004-10 PHASE3
NCT00204308 COMPLETED
HIV; Pregnancy
University of North Carolina, Chapel Hill
 2005-03 PHASE2
NCT00116805 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2005-06 PHASE3
NCT00117676 COMPLETED
Chronic Hepatitis B
Gilead Sciences
 2005-02 PHASE3
NCT00221286 TERMINATED
Chronic Hepatitis B; HIV Infections
University Hospital, Bonn
 2004-09 PHASE3
NCT00323687 COMPLETED
HIV-1 Infection
Gilead Sciences
 2004-09 PHASE4
NCT00055120 COMPLETED
HIV Infections; AIDS-Related Opportunistic Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2003-03 PHASE4
NCT00112047 COMPLETED
HIV Infections
Gilead Sciences
 2003-07 PHASE3
NCT00642291 COMPLETED
HIV Infections
Gilead Sciences
 2002-11 PHASE2
NCT00002416 COMPLETED
HIV Infections
Triangle Pharmaceuticals
 PHASE3
NCT00199121 UNKNOWN
HIV
Johann Wolfgang Goethe University Hospital
 PHASE4
NCT00389402 COMPLETED
HIV Infections
International Antiviral Therapy Evaluation Center
 2006-07 PHASE4
NCT00196599 COMPLETED
HIV Infections; Antiretroviral Naive
ANRS, Emerging Infectious Diseases
 1999-02 PHASE2
NCT00002362 SUSPENDED
HIV Infections
Triangle Pharmaceuticals
 1999-08 PHASE3
NCT00476983 WITHDRAWN
Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID
The HIV Netherlands Australia Thailand Research Collaboration
 PHASE2; PHASE3
NCT00017992 UNKNOWN
HIV Infections
Triangle Pharmaceuticals
 PHASE2
NCT00158457 COMPLETED
HIV Infection
French National Agency for Research on AIDS and Viral Hepatitis
 2004-06 PHASE3
NCT00106379 COMPLETED
HIV Infections
Gilead Sciences
 2004-10 PHASE4
NCT00036452 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 PHASE2
NCT00389194 COMPLETED
HIV Infections
International Antiviral Therapy Evaluation Center
 2006-04 PHASE4
NCT00006144 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 2000-10 PHASE2
NCT00087464 WITHDRAWN
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00196612 COMPLETED
HIV Infections
ANRS, Emerging Infectious Diseases
 2001-04 PHASE3
NCT00006208 UNKNOWN
HIV Infections
Triangle Pharmaceuticals
 2000-08 PHASE3
NCT00152061 COMPLETED
HIV Infections
Stanford University
 2005-01
NCT00127959 COMPLETED
HIV Infections; Hepatitis B
International Antiviral Therapy Evaluation Center
 2004-03 PHASE4
NCT00102206 COMPLETED
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
 PHASE2
NCT00002335 COMPLETED
HIV Infections
Glaxo Wellcome
 PHASE1
NCT00043966 COMPLETED
HIV Infections
Abbott
 2002-07 PHASE3
NCT00121017 WITHDRAWN
HIV Infection; Hepatitis C
Abbott
 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-14)

Check the Emtricitabine (FTC) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Emtricitabine functions as a nucleoside reverse transcriptase inhibitor that incorporates into synthesized viral nucleic acids to interrupt reverse transcription, thereby preventing the conversion of viral RNA into DNA and halting intracellular viral replication. By lowering viral load and supporting immune system restoration, this targeted enzymatic inhibition provides the clinical rationale for its evaluation in trials addressing HIV-1, HIV-2, and Hepatitis B viral infections.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.